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Abstract
Background: The Cystic Fibrosis Questionnaire (CFQ) is widely used in research as an instrument to measure
quality of life in patients with cystic fibrosis (CF). In routine patient care however, measuring quality of life is still
not implemented in guidelines. One of the reasons might be the lack of consensus on how to interpret CFQ
scores of an individual patient, because appropriate reference data are lacking. The question which scores reflect
normal functioning and which scores reflect clinically relevant problems is still unanswered. Moreover, there is no
knowledge about how healthy children and adolescents report on their quality of life (on the CFQ). With regard to
quality of life the effect of normal development should be taken into account, especially in childhood and
adolescence. Therefore, it is important to gain more knowledge about how healthy children and adolescents
report on their quality of life and if there are any difference in a healthy populations based on age or gender.
Without these data we cannot adequately interpret the CFQ as a tool in clinical care to provide patient-tailored
care. Therefore this study collected data of the CFQ in healthy children and adolescents with the aim to refer
health status of CF youngsters to that of healthy peers.
Methods: The CFQ was completed by 478 healthy Dutch children and adolescents (aged 6-20) in a cross-sectional
study.
Results: The majority of healthy children (over 65%) did not reach maximum scores on most domains of the CFQ.
Median CFQ-scores of healthy children and adolescents ranged from 67 to 100 (on a scale of 0-100) on the
different CFQ-domains. Significant differences in quality of life exist among healthy children and adolescents, and
these depend on age and gender.
Conclusions: Reference data of quality of life scores from a healthy population are essential for adequate
interpretation of quality of life in young patients with CF. Clinicians should be aware that the perception of health-
related quality of life is not as disease-specific as one might think and also relies on factors such as age, normal
maturation and gender.
Background
Cystic fibrosis (CF) is the most common autosomal-
recessive disease in the white population [1]. CF is,
despite advances in care and treatment modalities, still a
life threatening disease, involving especially the pulmon-
ary and gastrointestinal organs. CF poses a heavy burden
on patients and their families involving daily complex
and time-consuming treatments with medication and
demands of a healthy life style with sufficient nutrition
and exercise [2]. Fortunately, life expectancy of patients
with CF has improved dramatically in the recent years
due to early diagnosis and better treatment options [3].
With this increasing life expectancy, patients with CF
face new issues such as disease self management, devel-
opment towards personal autonomy and identity, ques-
tions concerning intimate relationships and family
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planning. It is now recognized that traditional measure-
ments of the physiological status (e.g. lung function and
body mass index) are inadequate to cover all aspects of
the impact of CF on daily life and on the broader issues
mentioned above [4]. Within this context, measuring
health-related quality of life has received growing atten-
tion in clinical care especially in pediatric and adoles-
cent care [5-7]. Disease specific instruments are
preferred above general instruments to measure health-
related quality of life in patients with CF because they
are designed to assess the symptoms and areas of func-
tioning that are most important for CF [4]. Although
several studies highlight the importance of incorporating
these patient reported outcomes in routine care, asses-
sing health-related quality of life is not yet implemented
in clinical guidelines. This is probably partly due to the
lack of appropriate reference values.
The Cystic Fibrosis Questionnaire (CFQ) was devel-
oped in 1997 as a CF specific questionnaire to measure
various domains of health-related quality of life of chil-
dren, adolescents and adults [8]. This instrument is now
available in 25 languages and it is the most widely
known instrument to measure a broad range of health-
related quality of life domains in CF, in research and in
clinical care. Health-related quality of life is not stable
in time, but varies due to different factors such as life
events, maturation, and changes in environment, treat-
ment, disease, and coping abilities. The CFQ is the only
disease specific questionnaire for patients with CF with
several age-appropriate versions, which make it possible
to follow patients with CF throughout their life span.
To date, however, there is no consensus on how to
interpret CFQ scores of an individual patient with CF
for clinical purposes, as no formal empirically derived
reference data are available. There is some evidence
about the minimally clinically important difference for
the CFQ, but in this research normal maturation in a
healthy population was not taken into account [9]. In
the Netherlands, only two small studies provide preli-
minary reference data for a small sample of Dutch CF-
patients [10,11]. In the first study psychometric charac-
teristics of the Dutch CFQ were assessed in 84 adoles-
cents and adults with CF aged 14-46 years. In the
second study 68 children with CF (mean age 11.3 years)
participated. Internal consistency was acceptable for
most domains of the CFQ (a = 0.43-0.92) and test-retest
reliability was high for all domain scores (0.72-0.98).
However, it is unknown which score range reflects nor-
mal functioning and which score range reflects clinically
relevant problems. Normality cannot be defined by
absence of complaints or functional impairment,
because even healthy subjects may experience symptoms
such as fatigue or suffer from anxiety or depressed feel-
ings from time to time. With regard to quality of life
the effect of normal development has to be taken into
account. For example, decreased mood and worries
about body image is common with increasing age, espe-
cially in adolescence. Therefore, changes over time in
quality of life may be due to progression of the disease
but may also be due to normal maturation. Therefore, it
is important to gain more knowledge about how healthy
children and adolescents report on their quality of life,
and if there are any differences based on age or gender
in a healthy population. Without these data we cannot
adequately interpret the CFQ as a tool in clinical care to
provide patient-tailored care. The aim of this study was
therefore to collect data on the CFQ in a healthy popu-
lation of children and adolescents and to increase
knowledge about this important patient reported out-
come instrument in the care for patients with cystic
fibrosis. We hypothesized that even healthy children
would not gain maximum scores on a disease-specific
health-related quality of life instrument.
Methods
Participants
In 2008, children and adolescents who met the inclusion
criteria were invited to participate in this study. Inclu-
sion criteria were: no chronic illness, not being under
treatment of a medical specialist, age between 6 and 20
years, and the capability to understand and read the
Dutch language. Children were recruited from primary
and secondary schools in the Eastern region of the
Netherlands. All primary and secondary schools in the
city Nijmegen (42) were invited to participate. Six
schools agreed to participate and in these schools classes
were selected at random. In secondary school classes
were selected from low to high education levels.
Measures
The Cystic Fibrosis Questionnaire (CFQ) is a widely
used disease specific questionnaire which measures dif-
ferent domains of health-related quality of life [12-15].
The CFQ was originally developed in France and
designed for CF-care and research goals [8]. Psycho-
metric properties of the Dutch version of the CFQ were
good according to Klijn et al.[10]. For the purpose of
the present study three Dutch versions were used:
-CFQ 6-11: interviewer administered version for
children between 6 and 11 years old consisting of 35
items divided into 8 domains (physical functioning,
emotional functioning, social functioning, body
image, eating disturbances, treatment burden,
respiratory symptoms, digestive symptoms).
-CFQ 12-13: self-administered version for children
between 12 and 13 years old consisting of the same
items and domains of the 6-11 version.
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-CFQ 14+: self-administered version for adolescents
and adults consisting of 50 items divided into 12
domains: the eight domains mentioned above and an
additional four domains (role functioning, vitality,
health perception and weight).
Response choices included ratings on a 4-point Likert
scale. These scores are standardized and range from 0
to 100 on every domain with higher scores correspond-
ing to better health-related quality of life. For the pur-
pose of this study the domain ‘treatment burden’ with
only disease specific questions about medical treatment
for CF was omitted. We chose to use the ‘old’ version of
the CFQ instead of the new CFQ-Revised, because the
new CFQ-Revised was not psychometrically tested in
the Netherlands and there are only small textual
changes compared to the ‘old’ version [10]. The three
versions of the Dutch CFQ are added as additional files
1, 2 and 3.
Procedure
Three primary schools and three secondary schools in
the Eastern region of the Netherlands took part in this
study. Formal approval from the local medical ethics
committee (CMO Arnhem-Nijmegen) was obtained.
Written informed consent was obtained according to
the principles of the local ethical committee. Legal care-
givers of children under 16 were asked permission as
well as adolescents above 12 years old. Participating
children and adolescents filled out the paper and pencil
version of the CFQ individually during a lesson in
school. Children between 6 and 11 had individually
interviewer administered questionnaires completed
according to the manual.
Analyses
Mean, median, standard deviation (SD) and range were
computed for each domain of the CFQ in this reference
population. Kolmogorov-Smirnov tests were used to test
whether the CFQ domain scores showed a normal dis-
tribution. Analyses were separated for the three age-ver-
sions (children aged 6-11, children aged 12-13, and
adolescents 14 -20 years old). The Mann-Whitney test
was used to assess potential differences between gender
and different age-groups. Data were analyzed with SPSS
version 14.0.
Results
Participants
478 schoolchildren and adolescents participated in this
study (table 1). Children and adolescents were derived
from a representative sample of all types of education,
ranging from low to high education levels.
CFQ-scores of healthy children and adolescents
Table 2 shows descriptive characteristics for the CFQ
domains in the three age groups. Median scores ranged
from as low as 67 (’Vitality’ in adolescents and ‘Diges-
tive symptoms’ in young children aged 6-11 years) to
maximum scores of 100 (’Body image’ in children aged
6-13 years ‘Eating disturbances’, ‘Role functioning’, and
‘Weight’ in adolescents). The Kolmogorov-Smirnov test
demonstrated that all domain scores on the different
CFQ-domains were not equally distributed (all
domains p < 0.05). In the age group 6-11 years no gen-
der differences were found. In the children aged 12
and 13 years old differences were found between boys
and girls on the domains ‘Emotional functioning’ and
‘Digestive symptoms’, where girls reported more pro-
blems than boys, but there was major overlap (Emo-
tional functioning median score female = 79 and male
= 83, p = 0.005; Digestive symptoms median score
female = 67 and male = 100, p = 0.025). In the adoles-
cent group, male adolescents reported better quality of
life status on the following domains: ‘Physical function-
ing’, ‘Health perception’, ‘Eating disturbances ’ and
‘Emotional functioning’ compared to female adoles-
cents (Physical functioning median score female = 92
and male = 96, p = 0.000; Health perception median
score female = 78 and male = 89, p < 0.001; Eating
disturbances median score female = 100 and male =
100, p = 0.007; Emotional functioning median score
female = 80 and male = 87, p = 0.003). These data
illustrate the heterogeneity between the different
domains of the CFQ in a healthy population.
Figure 1, 2 and 3 demonstrate the percentage of
healthy children for each age group who do not reach
maximum scores on the different domains of the CFQ.
Table 1 Sociodemographic characteristics of the sample
Variable Total (n = 478) n (%) Boys (n = 181) n (%) Girls (n = 297) n (%)
Age (years)
Mean ± S.D. (range) 14.52 ± 3.16 (6-20) 13.72 ± 3.09 (6-20) 15.00 ± 3.10 (6-20)
Age category (years)
Young children (aged 6-11 years) 60 (12.6%) 31 (52%) 29 (48%)
Elder children (aged 12-13 years) 120 (25.1%) 58 (48%) 62 (52%)
Adolescents (aged 14-20 years) 298 (62.3%) 92 (31%) 206 (69%)
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There is not one domain of the CFQ in which all
healthy children reach maximum scores.
Figures 4, 5 and 6 illustrate the trend for median
scores of the different CFQ domains for the three age
groups. These figures demonstrate that CFQ-scores are
different for the subsequent age groups. Some symp-
toms are more frequent in younger healthy children
than in healthy adolescents (e.g. digestive symptoms)
and some domains are decreasing when children grow
older (e.g. adolescents report more problems on the
domain ‘Body image’ than younger children).
Discussion
Principal findings
This study has four major outcomes. The first conclu-
sion is that the majority of healthy children do not
reach maximum scores on many domains of the CFQ.
The percentage of healthy children and adolescents
reaching maximum scores on the different CFQ-
domains was remarkably low with an average of 34.8%
over the different domains. For example, in the domain
‘Vitality’’ 99.7 percent of all healthy adolescents did
experience feelings of tiredness and exhaustion to some
degree. This finding is in agreement with the statement
that normality cannot be defined as the absence of
symptoms or functional impairment.
The second major finding is the heterogeneity of
scores between different CFQ-domains in healthy sub-
jects. Median scores on the different CFQ-domains var-
ied between 67 and 100. For example, digestive
symptoms (e.g. abdominal pain, flatulence, and diarrhea)
are apparently quite common in young healthy children
(median score = 67 on domain ‘Digestive symptoms’ in
children aged 6-11 years old). In contrast, eating
Table 2 Descriptive analyses (mean, SD, range, median and % maximum scores) of CFQ domain scores in healthy
children (n = 478)
Variable Mean SD Range Median n maximum score
(% maximum scores)
Healthy young children (aged 6-11) (n = 60)
Age 8.93 1.58
Physical functioning 89.07 14.27 22-100 94 19 (31.7)
Emotional functioning 83.27 12.09 54-100 88 5 (8.3)
Eating disturbances 90.83 11.31 56-100 95 30 (50)
Social functioning 89.65 12.91 48-100 95 23 (16.7)
Body image 95.78 8.37 67-100 100 44 (73.3)
Respiratory symptoms 88.70 11.55 50-100 92 15 (25)
Digestive symptoms 80.13 20.49 33-100 67 28 (46.7)
Healthy elder children (aged 12-13) (n = 120)
Age 12.30 0.93
Physical functioning 88.41 13.25 17-100 92 47 (39.2)
Emotional functioning 79.89 14.52 17-100 83 8 (6.7)
Eating disturbances 85.57 16.74 33-100 89 47 (39.2)
Social functioning 84.95 12.97 38-100 86 27 (22.5)
Body image 93.20 11.93 44-100 100 79 (65.8)
Respiratory symptoms 90.68 10.23 33-100 92 35 (29.2)
Digestive symptoms 82.37 18.70 33-100 84 60 (50)
Healthy adolescents (aged 14-20) (n = 298)
Age 16.53 1.67
Physical functioning 90.04 11.66 38-100 92 84 (28.2)
Vitality 63.33 13.80 33-100 67 1 (0.3)
Emotional functioning 78.20 14.37 7-100 80 15 (5)
Eating disturbances 93.52 12.03 11-100 100 193 (64.8)
Health perceptions 80.78 16.74 33-100 84 74 (24.8)
Social functioning 90.26 9.14 33-100 94 73 (24.5)
Body image 84.59 17.77 22-100 89 126 (42.3)
Role functioning 93.81 7.94 67-100 100 157 (52.7)
Weight 93.42 19.47 0-100 100 260 (87.2)
Respiratory symptoms 92.21 11.34 33-100 94 131 (44)
Digestive symptoms 89.98 13.82 0-100 89 144 (48.3)
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disturbances did not occur very often in this healthy age
group (median score 95).
The third finding is that median scores on different
domains of the CFQ differed according to age. As men-
tioned above, digestive symptoms occurred frequently in
healthy young children aged 6-11 years old (median
score 67), in contrast to the relative absence of digestive
symptoms in the age group of healthy adolescents, in
which digestive symptoms were quite rare (median
score 89). Body image becomes more problematic when
children grow into adolescence. This finding is in agree-
ment with previous research in which most general
quality of life scales (e.g. emotional functioning, physical
and psychological wellbeing and self-perception)
decrease from childhood into adolescence [16,17]. A
community based study showed that abdominal pain is
more frequently reported in childhood than in adoles-
cence [18].
The last major finding is that there were some sex-
related differences. In 6-11 year old healthy children
there were no differences in any domain of the CFQ
between boys and girls. In children aged 12-13 years
old, girls reported more problems with emotional func-
tioning and digestive symptoms, but there was major
overlap. In the age-group 14-20 years, boys reported
better quality of life on the domains: ‘Physical function-
ing’, ‘Health perception’, ‘Eating disturbances’ and ‘Emo-
tional functioning’. But also in these domains there was
considerable overlap in scores. These findings are in
agreement with observations that in general, female ado-
lescents have a poorer perception of their own health
and report more somatic problems than their male
counterparts [17,18]. These data indicate that it is
important to take into account gender in the evaluation
of health-related quality of life.
Methodological considerations and implications for future
research
The major strength of our study is that, to our knowl-
edge, this is the first study in which data of a large
group of healthy children and adolescents was used to
expand knowledge on a disease specific instrument for
CF. These data help to improve the interpretation of
health-related quality of life assessment in CF using
the CFQ. However, some methodological issues need
further comment. In the adolescent group we had a
disproportional high rate of females in our study-sam-
ple, due to the particular schools which participated.
This may have influenced our results, in some way.
The difference in the domain eating disturbances
between young children and adolescents may be even
bigger. The difference between emotional functioning
of young children aged 12-13 years and adolescents
might be smaller in reality.
It is impossible to determine whether differences in
CFQ scores between the three age groups are due to
true age differences or whether differences in CFQ
Figure 1 Percentage of healthy children aged 6-11 years NOT
reaching maximum scores on the different CFQ domains (n =
60).
Figure 2 Percentage of healthy children aged 12-13 years NOT
reaching maximum scores on the different CFQ domains (n =
120).
Figure 3 Percentage of healthy adolescents aged 14-20 years
NOT reaching maximum scores on the different CFQ domains
(n = 298).
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scores are caused by the fact that different, age-specific
questionnaires and procedures were employed for each
age group. In the youngest age group the CFQ was
administered individually with an interviewer, whereas
the older children and adolescents filled out the CFQ in
the classroom without individual help. Because only
Dutch children and adolescents were included, it is
unknown whether our results are also representative for
other countries. Future research should collect reference
data from healthy adults and from a large clinical popu-
lation of CF patients in all age groups in different coun-
tries. A longitudinal study would be needed to assess
how health-related quality of life evolves over time in
individuals.
Figure 4 Median scores for the three age groups on three domains of the CFQ (physical functioning, emotional functioning and social
functioning). a Differences between physical functioning are not significant in the three age-groupsb Difference between emotional functioning
is significant between healthy young children aged 6-11 years and healthy adolescents (p < 0.05, Mann-Withney)c Difference between social
functioning is significant between healthy children aged 6-11 years and healthy children aged 12-13 years (p < 0.01, Mann-Whitney), and
between healthy young children aged 12-13 years and healthy adolescents (p < 0.01, Mann-Whitney).
Figure 5 Median scores for the three age groups on two domains of the CFQ (eating disturbances and body image). a Difference
between body image is significant between healthy young children aged 6-11 years and healthy adolescents (p < 0.01, Mann-Whitney), and
between healthy young children aged 12-13 years and adolescents (p < 0.01, Mann-Whitney)b Difference between eating disturbance is
significant between healthy young children aged 6-11 years and healthy adolescents (p < 0.05, Mann-Whitney), and between healthy young
children aged 12-13 years and adolescents (p < 0.01, Mann-Whitney).
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Obviously, the CFQ can not be used as a quality of life
measure for healthy children because it does not cover
all aspects of quality of life in healthy children. It is
especially designed for the evaluation of health-related
quality of life of patients with CF. Therefore, the pri-
mary objective of this study is to optimize the interpre-
tation of CFQ-scores in young patients with CF. The
CFQ allows specific issues to be identified, addressed
and monitored over time. However comparison against
‘norms’ is not always wanted. This new data allows us
to see whether we are concerned about a CFQ score
which is inherently ‘normal’ or not for the CF child’s
age and gender, but it must also be related to whether it
is perceived as a problem regardless of whether it relates
to the influence of the CF on the child or not.
Consequences for patient care
This study demonstrates that the majority of healthy
children and adolescents do not gain maximum scores
on a disease specific health-related quality of life instru-
ment and that there are many differences between the
outcomes on the different domains and age groups. This
is important information if we want to interpret the
health-related quality of life for individual patients based
on the CFQ for treatment purposes. In healthy adoles-
cents aged 14-20 most subjects scored on the domain
‘Vitality’ under 70 (median: 67), indicating that many
healthy adolescents report feelings of tiredness, lack of
energy or exhaustion. Therefore, a ‘Vitality’ score of 70
in an adolescent with CF does not automatically indicate
a relation to his or her disease, but it can also be related
to other factors NOT related to CF. Similarly, in chil-
dren with CF, a suboptimal CFQ-score in the domain
‘Digestive symptoms’, does not always implicate that
these symptoms are due to their disease because recur-
rent abdominal pain is a common complaint in normal
childhood and in many cases an underlying cause is not
found [19]. However, a score of 70 in a young boy (aged
7 years) with CF on the domain ‘Body image’ is low
compared to age-matched healthy controls, and deserves
more CF-specific attention. This study indicates that for
the clinical interpretation of health-related quality of life
of an individual patient with CF it is essential to pay
attention to contextual non-disease specific factors such
as age, maturation and gender. Incorporating disease
specific questionnaires that assess different domains of
quality of life in routine CF care may improve our
understanding of the impact of CF on daily life [7]. A
better understanding of this impact can facilitate com-
munication between health care providers and patients.
In addition, more patient-tailored treatments may be
developed. As previous research has shown, better com-
munication can improve treatment adherence [20-22].
Improving treatment adherence can improve quality of
life in a majority of CF-patients.
Conclusion
The results of the present study provide us with a tool
to optimize the interpretation of CFQ-scores in young
patients with CF. Clinicians should be aware that the
Figure 6 Median scores for the three age groups on two domains of the CFQ (respiratory symptoms and digestive symptoms). a
Difference between respiratory symptoms is significant between healthy young children aged 6-11 years and healthy adolescents (p < 0.01,
Mann-Whitney), and between healthy young children aged 12-13 years and adolescents (p < 0.01, Mann-Whitney)b Difference between digestive
symptoms is significant between healthy young children aged 6-11 years and healthy adolescents (p < 0.01, Mann-Whitney), and between
healthy young children aged 12-13 years and adolescents (p < 0.01, Mann-Whitney).
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perception of health-related quality of life is not as dis-
ease-specific as one might think and also relies on fac-
tors such as age, maturation and gender. Health-related
quality of life scores based on the CFQ of individuals
with CF should be interpreted within the context of
normal development. A careful interpretation of health-
related quality of life helps to improve patient-tailored
treatment.
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